Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Income from Continuing Operations: 2010-2025

Historic Income from Continuing Operations for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to -$91.3 million.

  • Iovance Biotherapeutics' Income from Continuing Operations fell 9.23% to -$91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.7 million, marking a year-over-year increase of 2.99%. This contributed to the annual value of -$372.2 million for FY2024, which is 16.18% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Income from Continuing Operations is -$91.3 million, which was up 18.28% from -$111.7 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Income from Continuing Operations ranged from a high of -$78.6 million in Q4 2024 and a low of -$116.4 million during Q4 2023.
  • For the 3-year period, Iovance Biotherapeutics' Income from Continuing Operations averaged around -$103.2 million, with its median value being -$107.4 million (2023).
  • In the last 5 years, Iovance Biotherapeutics' Income from Continuing Operations skyrocketed by 32.47% in 2024 and then fell by 15.05% in 2025.
  • Quarterly analysis of 3 years shows Iovance Biotherapeutics' Income from Continuing Operations stood at -$116.4 million in 2023, then soared by 32.47% to -$78.6 million in 2024, then declined by 9.23% to -$91.3 million in 2025.
  • Its Income from Continuing Operations stands at -$91.3 million for Q3 2025, versus -$111.7 million for Q2 2025 and -$116.2 million for Q1 2025.